INTERCEPT PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 19, 2023, Intercept Pharmaceuticals, Inc. issued a press release, which is attached as Exhibit 99.1 and incorporated by reference, announcing that the U.S. Food and Drug Administration (FDA) has accepted for filing its resubmission of its New Drug Application (NDA) for obeticholic acid (OCA) seeking accelerated approval for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit Number Description

  99.1           Press Release
104            Cover Page Interactive Data File (embedded as Inline XBRL document)

The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed.

© Edgar Online, source Glimpses